Bresagen rights issue cancelled

By Melissa Trudinger
Wednesday, 02 March, 2005

Bresagen (ASX:BGN) has cancelled its non-renounceable rights issue which the company had hoped would raise AUD$8.8 million, citing failure to meet the minimum subscription of $2 million.

The company said its board had decided not to use a 90-day shortfall placement period open to directors, as the company's shares have recently been trading below the rights offer issue price of $0.095. All funds received will be returned to shareholders.

The company will instead access the convertible notes facility approved by shareholders in December. A shareholder meeting will be called in May to deal with this and related issues.

Bresagen was reinstated to the ASX in December after being in voluntary adminstration for almost a year following the failed spinout of the company's protein pharmaceuticals business.

The company was rescued by Queensland biotech CBio, which took a 51 per cent stake in the company, as well as funding the convertible notes facility, along with the Australian Technology Investment Fund.

Related News

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...

RSV immunisation program for babies slashes hospital stays

An Australian-first study has demonstrated the effectiveness of immunisation against respiratory...

A targeted treatment option for psoriasis

New research from MedUni Vienna paves the way for the development of a therapy that not only...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd